Self Defining Memories in Women Victims of Intimate Partner Violence. (SOI-MEM)

July 29, 2020 updated by: University Hospital, Toulouse

Self Defining Memories in Women Victims of Intimate Partner Violence: a Pilot Study.

A recent report by the World Health Organization demonstrated that 30 % of women worldwide have been victims of intimate-partner violence (IPV). IPV is a public health problem thus it seems important to propose relevant care. It is difficult to carry out an effective therapy. Psychological care is based on cognitive abilities but these women have cognitive impairment. Few studies investigated their cognitive dysfunction. Investigators suggest in this study an exploration of the Self Defining Memories (SDM) which can highlight the loss of identity of these women and a new target of therapy.

Study Overview

Detailed Description

Intimate partner violence among women is associated to identity problems. Indeed, the victims have a poor self esteem and difficulties to express their own wishes. In this study investigators suggest an analysis of a type of memory, that is known to be essential, to profile an identity functioning: self-defining memories. To date, no study has explored SDM in women with IPV. The characteristics of the SDM in women victims of IPV will be compared to a group of women who has never been diagnosed in this situation. Those memories could be used in therapy. A French adaptation of the questionnaire proposed by Singer & Moffitt (1992) will be used (Berna et al., 2011a, 2011b) for the assessment of SDM.

Four elements will be study: specificity, meaning, content, affect.

The two groups will have two visits:

  • the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms;
  • the last to characterize the SDM.

Study Type

Interventional

Enrollment (Anticipated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

For all participants:

  • French mother tongue.
  • Informed consent.
  • Affiliated to social security

For women who are victims of IPV only:

  • Having at least two physical aggressions
  • To meet criterion A of the diagnosis of PTSD according to the Diagnostic and Statistical Manual of Mental Disorders DSM (DSM-5) (evaluated using the Mini International Neuropsychiatric Interview, MINI)

For women of the control group only:

- None a victim of IPV

Exclusion Criteria:

For all participants:

  • Neurological pathology, brain damage.
  • History of head trauma with loss of consciousness.
  • Severe, progressive somatic pathology
  • Psychotherapy in progress
  • Taking psychotropic drugs or beta-blockers (because of their potential impact on memory capacity)
  • Pregnant or lactating women
  • Under a legal regime for the protection of adults

For women who are victims of IPV only:

  • Antecedent or presence of PTSD other than that related to IPV
  • History or presence of progressive mental disorders (Axis I DSM-5 - evaluated using Mini International Neuropsychiatric Interview, MINI)

For women of the control group only:

History or presence of progressive mental disorders including PTSD (Axis I DSM-5 - evaluated using Mini International Neuropsychiatric Interview, MINI)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intimate partner violence
The women in this arm must have suffered at least two physical aggressions. They will be recruited in the study as part of their coming to the consultation of intentional injury of the medico-legal unit of the University Hospital Toulouse.

This group will have two visits:

  • the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing assessment measures called MINI, PCL-5, BDI-II ;
  • the last to characterize the SDM by defining 5 personal memories
Active Comparator: Control group
The women in this group are women who have never experienced domestic violence or have experienced a potentially traumatic event. These women will be recruited by a call for volunteers.

This group will have two visits:

  • the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing MINI questionary;
  • the last to characterize the SDM by and defining 5 personal memories

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Description of five Self Defining Memories.
Time Frame: 7 to 10 days after inclusion visit
These memories are declined in four dimensions: specificity, content, meaning and emotional valence. Investigator will get a proportion of memories which are specific, which are negative, positive or neutral, which have an integrative meaning and which are associated to violence for IPV victims. The results of Self Defining Memories will be compared between a group of IPV victims and a control group.
7 to 10 days after inclusion visit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportions of SDM whose content is associated with discomfort in IPV victims compared to those of control.
Time Frame: 7 to 10 days after inclusion visit
7 to 10 days after inclusion visit
Proportions of SDM whose emotional valence is associated with a feeling of redemption or contamination in IPV victims compared to those of control.
Time Frame: 7 to 10 days after inclusion visit
7 to 10 days after inclusion visit
Relationships between the 4 dimensions of SDM and psychotraumatic symptoms in IPV victims.
Time Frame: 7 to 10 days after inclusion visit
These symptoms will be measured via the Posttraumatic Stress Disorder Checklist (PCL-5 scale).This is a self-questionnaire to assess the main symptoms of Post traumatic stress disorder. It has 20 items that evaluate the intensity and frequency of symptoms in the previous month using scores from 1 to 4.The higher the score, the more important the trauma.
7 to 10 days after inclusion visit
Relationships between the 4 dimensions of SDM and depressive symptoms in IPV victims.
Time Frame: 7 to 10 days after inclusion visit

These symptoms will be measured via the Beck Depressin Inventory (BDI) scale: this is a self-questionnaire to assess the severity of depressive symptoms using 21 items. Once the test is completed, a score is made by decounting, then compared according to the score, thus determining the severity of the depression:

0 - 9: indicates a minor depression 10 - 18: indicates slight depression 19 - 29: indicates moderate depression 30 - 63: indicates severe depression

7 to 10 days after inclusion visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Damien PIERRE, MD, Chu Toulouse

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 6, 2020

Primary Completion (Anticipated)

November 1, 2021

Study Completion (Anticipated)

December 1, 2021

Study Registration Dates

First Submitted

April 4, 2019

First Submitted That Met QC Criteria

April 5, 2019

First Posted (Actual)

April 8, 2019

Study Record Updates

Last Update Posted (Actual)

July 31, 2020

Last Update Submitted That Met QC Criteria

July 29, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • RC31/19/0051

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Domestic Violence

Clinical Trials on Assessment measures MINI, PCL5 and BDI-II and definition of 5 SDM

Subscribe